Abstract
Ropivacaine is a new amide local anaesthetic, which is the first commercially available in its category as a pure S-(-) enantiomer. In most recent studies [40], ropivacaine exhibited a very close pharmacodynamic profile to equipotent doses of bupivacaine. Concentrations of 0.5percent, 0.75percent and 1percent (5, 7.5 and 10 mg / mL, respectively) ropivacaine are used for intraoperative anaesthesia, while the concentration of 0.2percent (2 mg / mL) is preferred for postoperative analgesia, either alone or in combination with opioids and / or clonidine. Ropivacaine is responsible for excellent postoperative analgesia following epidural and peripheral perineural injections, using single-shot injections and continuous infusions. Differential sensory / motor block is only apparent at low concentrations (0.2percent and less). A significant amount of recent literature focuses on its use for peripheral blocks of the lower limbs, i.e. sciatic and femoral nerve blocks. The primary benefit of ropivacaine is its lower toxicity, mainly lower cardiotoxicity, following accidental intravascular injection. This higher therapeutic index leads to an improved safety profile as compared with potent local anaesthetics such as racemic bupivacaine. For that reason, ropivacaine is a good choice for both intraoperative and postoperative regional anaesthesia and analgesia.
Keywords: Ropivacaine, local anaesthetic, Epidural Administration, LOWER LIMB SURGERY, Sciatic Nerve Blocks, Postoperative Analgesia
Current Topics in Medicinal Chemistry
Title: Clinical Application of Ropivacaine for the Lower Extremity
Volume: 1 Issue: 3
Author(s): Jean-Jacques Eledjam, Jacques Ripart and Eric Viel
Affiliation:
Keywords: Ropivacaine, local anaesthetic, Epidural Administration, LOWER LIMB SURGERY, Sciatic Nerve Blocks, Postoperative Analgesia
Abstract: Ropivacaine is a new amide local anaesthetic, which is the first commercially available in its category as a pure S-(-) enantiomer. In most recent studies [40], ropivacaine exhibited a very close pharmacodynamic profile to equipotent doses of bupivacaine. Concentrations of 0.5percent, 0.75percent and 1percent (5, 7.5 and 10 mg / mL, respectively) ropivacaine are used for intraoperative anaesthesia, while the concentration of 0.2percent (2 mg / mL) is preferred for postoperative analgesia, either alone or in combination with opioids and / or clonidine. Ropivacaine is responsible for excellent postoperative analgesia following epidural and peripheral perineural injections, using single-shot injections and continuous infusions. Differential sensory / motor block is only apparent at low concentrations (0.2percent and less). A significant amount of recent literature focuses on its use for peripheral blocks of the lower limbs, i.e. sciatic and femoral nerve blocks. The primary benefit of ropivacaine is its lower toxicity, mainly lower cardiotoxicity, following accidental intravascular injection. This higher therapeutic index leads to an improved safety profile as compared with potent local anaesthetics such as racemic bupivacaine. For that reason, ropivacaine is a good choice for both intraoperative and postoperative regional anaesthesia and analgesia.
Export Options
About this article
Cite this article as:
Eledjam Jean-Jacques, Ripart Jacques and Viel Eric, Clinical Application of Ropivacaine for the Lower Extremity, Current Topics in Medicinal Chemistry 2001; 1 (3) . https://dx.doi.org/10.2174/1568026013395317
DOI https://dx.doi.org/10.2174/1568026013395317 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
C1-Inhibitor: Structure, Functional Diversity and Therapeutic
Development
Current Medicinal Chemistry The Protective Function of Human C-reactive Protein in Mouse Models of Streptococcus pneumoniae Infection
Endocrine, Metabolic & Immune Disorders - Drug Targets Immune Cell Entry to Central Nervous System - Current Understanding and Prospective Therapeutic Targets
Endocrine, Metabolic & Immune Disorders - Drug Targets Brain Injury Associated with Widely Abused Amphetamines: Neuroinflammation, Neurogenesis and Blood-Brain Barrier
Current Drug Abuse Reviews Antioxidants and Neuroprotection in the Adult and Developing Central Nervous System
Current Medicinal Chemistry Overview of Brain Tumor Stem Cells – Implications for Treatment
Current Signal Transduction Therapy Optimization of Drug Safety Profile in Inflammatory Bowel Disease Through a Personalized Approach
Current Drug Targets Calpain Inhibition: A Therapeutic Strategy Targeting Multiple Disease States
Current Pharmaceutical Design Intravenous Immunoglobulins for Alzheimer's Disease
Current Alzheimer Research Microemulsion and Microemulsion-Based Gels for Topical Antifungal Therapy with Phytochemicals
Current Pharmaceutical Design An Update to Enterococcal Bacteremia: Epidemiology, Resistance, and Outcome
Infectious Disorders - Drug Targets Structure Guided Design of Biotin Protein Ligase Inhibitors for Antibiotic Discovery
Current Topics in Medicinal Chemistry A RP-HPLC-UV Method with Solid Phase Extraction for Determination of Cefepime in Total Nutrient Admixtures: Application to Stability Studies
Current Pharmaceutical Analysis Recent Advances in Glycosidase Probes Used in Escherichia Coli Detection
Current Medicinal Chemistry Metabotropic Glutamate Receptor 5 in Down's Syndrome Hippocampus During Development: Increased Expression in Astrocytes
Current Alzheimer Research Structural Vaccinology: A Three-dimensional View for Vaccine Development
Current Topics in Medicinal Chemistry TB Diagnostics – Old and New
Current Respiratory Medicine Reviews Drug Target in Eosinophilic Meningitis Caused by Angiostrongylus cantonensis
Infectious Disorders - Drug Targets Nanoneuromedicines for Neurodegenerative Diseases
Nanoscience & Nanotechnology-Asia Selection of Potential Pharmacological Targets in ALS Based on Whole- Genome Expression Profiling
Current Medicinal Chemistry